Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Ordinary shares, nominal value 0.002 GBP per share
-
Shares outstanding
-
145,993,531
-
Total 13F shares
-
143,756,351
-
Share change
-
+15,431,787
-
Total reported value
-
$3,595,234,186
-
Put/Call ratio
-
60%
-
Price per share
-
$25.01
-
Number of holders
-
146
-
Value change
-
+$388,743,626
-
Number of buys
-
86
-
Number of sells
-
64
Institutional Holders of Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA) as of Q4 2025
As of 31 Dec 2025,
Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA) was held by
146 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
143,756,351 shares.
The largest 10 holders included
Medicxi Ventures Management (Jersey) Ltd, Avoro Capital Advisors LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Index Venture Life Associates VI Ltd, FMR LLC, GENERAL ATLANTIC, L.P., FARALLON CAPITAL MANAGEMENT LLC, TCG Crossover Management, LLC, JANUS HENDERSON GROUP PLC, and Siren, L.L.C..
This page lists
146
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.